摘要
目的评估应用曲妥珠单抗与紫杉醇新辅助化疗人表皮生长因子受体2(HER2)阳性局部乳腺癌晚期患者的疗效。方法选择2017年2月—2018年10月期间入某医院诊治的62例HER2阳性局部乳腺癌晚期患者,按随机数表法进行分组,单一组(31例)单独行曲妥珠单抗治疗,联合组(31例)行曲妥珠单抗与紫杉醇新辅助化疗联合治疗。对比两组患者血清相关指标、临床疗效以及药物毒副反应。结果治疗后联合组患者的糖类抗原125(CAI125)、肿瘤特异性生长因子(TSGF)、癌胚抗原(CEA)肿瘤标志物表达水平均低于单一组;联合组治疗有效率(64.52%)高于单一组(38.71%),差异有统计学意义(P<0.05)。结论对HER2阳性局部乳腺癌晚期患者应用曲妥珠单抗与紫杉醇新辅助化疗的疗效较好,可抑制肿瘤细胞增殖,有效控制病情进展,值得推广。
Objective To evaluate the efficacy of trastuzumab and paclitaxel neoadjuvant chemotherapy for HER2 positive patients with locally advanced breast cancer.Methods Sixty two patients with HER2 positive local advanced breast cancer admitted to a hospital from February 2017 to October 2018 were selected and grouped according to the random number table method.The single group(31 cases)received trastuzumab alone,and the combined group(31 cases)received trastuzumab combined with paclitaxel neoadjuvant chemotherapy.The serum related indexes,clinical efficacy and drug toxicity were compared between the two groups.Results After the treatment,the expression levels of CAI 125,TSGF and CEA in the combined group were lower than those in the single group,and the effective rate of the combined group(64.52%)was higher than that of the single group(38.71%)with statistical significance(P<0.05).Conclusion The efficacy of trastuzumab and paclitaxel neoadjuvant chemotherapy for HER2 positive patients with advanced breast cancer is better.It can inhibit the proliferation of cancer cells,effectively control the progress of the disease,and has good safety.It is worth promoting.
作者
张昆
ZHANG Kun(Department of Thyroid and Breast Surgery,Second People's Hospital of Nanyang City,Nanyang 473000,Henan,China)
出处
《中国校医》
2020年第3期187-188,195,共3页
Chinese Journal of School Doctor
